Sign up for free insights newsletter
VN

Volitionrx Ltd

VNRXUnited States

Need professional-grade analysis? Visit stockanalysis.com

$0.20
+7.48%
End of day
Market Cap

$27.85M

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino0.460.97-1.02-1.31-1.05-0.74
Calmar5.142.59-1.26-1.23-0.80-0.16
Sharpe0.210.44-0.55-0.92-0.66-0.50
Omega1.161.240.910.700.890.91
Martin8.903.84-1.98-1.66-1.34-0.18
Ulcer3.7215.5930.0853.7747.5738.54

Volitionrx Ltd (VNRX) Price Performance

Volitionrx Ltd (VNRX) trades on United States in USD. The company is classified in the Healthcare sector under the In Vitro & In Vivo Diagnostic Substances industry. The stock currently trades at $0.20, up 7.48% from the previous close.

Over the past year, VNRX has traded between a low of $0.19 and a high of $0.92. The stock has lost 60.6% over this period. It is currently 78.1% below its 52-week high.

Volitionrx Ltd has a market capitalization of $27.85M.

About Volitionrx Ltd

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$1.47M
EBITDA
$-21,653,004
Profit Margin
-2209.79%
EPS (TTM)
-0.23
Book Value
-0.32

Technical Indicators

52 Week High
$0.94
52 Week Low
$0.17
50 Day MA
$0.25
200 Day MA
$0.47
Beta
1.36

Valuation

Trailing P/E
N/A
Forward P/E
-2.28
Price/Sales
18.92
Price/Book
-0.65
Enterprise Value
$34.97M